REDX
PHARMA PLC
("Redx"
or the "Company")
Notice of Annual General
Meeting
Alderley Park, UK, 16 February 2024 Redx (AIM:REDX), the clinical-stage biotechnology company
focused on discovering and developing novel, small molecule,
targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that its Annual
General Meeting will be held at 11am on 14 March 2024 at the
offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N
4BQ.
Following the announcement of
preliminary results for the financial year ended 30 September 2023
on 15 December 2023, the Company announces that the Annual Report
and Accounts and notice of Annual General Meeting have now been
posted to shareholders. The Annual Report and Accounts and notice
of Annual General Meeting are also available to view on Redx's
website at www.redxpharma.com.
Shareholders are strongly encouraged
to vote by proxy, appointing the Chair of the meeting, using the
form of proxy distributed with the notice of meeting, to ensure
their vote counts. The form of proxy is also available in the
investor resources section of the Company's
website: www.redxpharma.com
Completed proxies should be returned
to:
Equiniti
Aspect House
Spencer Road
Lancing
BN99 6DA
and must be received by 11am on 12
March 2024 to be valid.
|
For
further information, please contact:
|
|
|
|
|
|
|
|
|
|
Redx Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
|
Matt Davis/ Adam Dawes
|
|
|
|
|
|
|
|
WG
Partners LLP (Joint Broker)
|
T: +44 (0)203 705 9330
|
|
|
Claes Spång/ Satheesh Nadarajah/
David Wilson
|
|
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
T: +44 (0)207 886 2500
|
|
|
Rupert Dearden/ Freddy Crossley/
Emma Earl
|
|
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
|
Simon Conway/ Ciara
Martin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company's lead
fibrosis product candidate, the selective ROCK2 inhibitor,
zelasudil (RXC007), is in development for interstitial lung disease
and is undergoing a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for
the treatment of fibrostenotic Crohn's disease, is progressing
towards the clinic with a Clinical Trial Application (CTA)
submitted during Q4 2023. Redx's lead oncology product candidate,
the Porcupine inhibitor RXC004, being developed as a targeted
treatment for Wnt-ligand dependent cancers, is expected to report
anti-PD-1 combination Phase 2 data during the first half of 2024,
following which Redx will seek a partner for ongoing
development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
